Orbimed Capital, Director: ARS Pharmaceuticals SPRY Buy · Filed 23/08/31

Trade details

Type: Insider buy
Amount: $3,100,000
Shares · price: 500,000 sh · $6.20 a share
Held after: 8,019,187 sh
Stock: ARS Pharmaceuticals SPRY
Person: Orbimed CapitalDirector
Trade date: 23/08/29
Filed: 23/08/31
Days to filing: 2 days

9 insiders bought this week

Insiders buying this week: 9 insiders
Holding change: +6.6%

ARS Pharmaceuticals trades, last 26 weeks

What else happened in ARS Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 23/07/30~23/09/28

Orbimed Capital's recent trades

Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$1.4M
29,385 sh
$1.4M
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$80.3K
1,747 sh
$80.3K
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$433.9K
10,243 sh
$433.9K
Filed 06/15
Traded 06/15
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$7.5M
1,689,189 sh
$7.5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$5M
1,126,126 sh
$5M
Filed 04/23
Traded 04/21